Tarperprumig for Vasculitis
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called tarperprumig for individuals with ANCA-associated vasculitis, a condition that inflames blood vessels. The main goal is to determine if tarperprumig is safe and tolerable for patients. Participants will be divided into two groups to receive either different doses of tarperprumig or a placebo (a substance with no active drug). Ideal candidates for this trial include those newly diagnosed with ANCA-associated vasculitis or experiencing a relapse, especially if their condition might require treatment with certain strong medications. As a Phase 2 trial, this research focuses on assessing the treatment's effectiveness in an initial, smaller group of people.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
Is there any evidence suggesting that tarperprumig is likely to be safe for humans?
Research has shown that tarperprumig is being tested for its safety in treating ANCA-associated vasculitis. Specific safety information remains limited. However, the current phase of the trial shows that researchers are still gathering initial safety data. They are closely monitoring how participants handle the drug and are looking for any side effects. No major safety problems have been reported so far. This is a positive sign, but more information is needed to fully understand the treatment's safety.12345
Why do researchers think this study treatment might be promising for vasculitis?
Researchers are excited about Tarperprumig for treating vasculitis because it offers a novel approach compared to standard treatments like corticosteroids and immunosuppressants. Unlike these conventional therapies, which broadly suppress the immune system, Tarperprumig targets specific pathways involved in inflammation. This precision could mean fewer side effects and a more effective reduction of symptoms. Additionally, Tarperprumig might provide faster relief, potentially improving patient outcomes more quickly than current options.
What evidence suggests that tarperprumig might be an effective treatment for vasculitis?
Research suggests that tarperprumig may help treat conditions like vasculitis by targeting the complement alternative pathway, a part of the immune system. This pathway can become overly active in certain diseases, leading to inflammation and damage. Animal studies found tarperprumig to be safe and well-tolerated at specific doses. Although human studies provide limited information, these early results offer hope that tarperprumig could be effective for people with vasculitis. Participants in this trial will receive either tarperprumig at one of two dose regimens or a placebo, enabling researchers to evaluate its effectiveness and safety in treating vasculitis.14567
Are You a Good Fit for This Trial?
This trial is for adults with ANCA-associated vasculitis, which is a type of inflammation in the blood vessels. It's open to those who have just been diagnosed or are experiencing a relapse.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either tarperprumig or placebo to evaluate safety and tolerability
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Tarperprumig
Find a Clinic Near You
Who Is Running the Clinical Trial?
Alexion Pharmaceuticals, Inc.
Lead Sponsor
Dr. Alberto R. Martinez
Alexion Pharmaceuticals, Inc.
Chief Medical Officer since 2010
MD from University of Sao Paulo
Marc Dunoyer
Alexion Pharmaceuticals, Inc.
Chief Executive Officer since 2021
PhD in Molecular Biology